Phase II study of high-dose methotrexate in the treatment of patients with non-small cell carcinoma of the lung: an Eastern Cooperative Oncology Group study.

Abstract

Twenty-eight patients with inoperable non-small cell carcinoma of the lung were treated with high-dose methotrexate with citrovorum factor rescue. One patient (4%) responded with a partial regression of the tumor. Three patients had severe or life-threatening complications: acute renal failure, acute shortness of breath, and bone marrow suppression, respectively. There is 98% confidence that the true response rate for this therapy is less than 20%. The results of this study demonstrate that high-dose methotrexate with citrovorum factor rescue, in the schedule utilized, is not effective in the treatment of patients with non-small cell carcinoma of the lung.

• Authors: D S Ettinger, K E Stanley, J S Nystrom
• Journal: Cancer treatment reports (Cancer Treat Rep) 1980 Oct-Nov Vol. 64 Issue 10-11 Pg. 1017-21 ISSN: 0361-5960 [Print] United States
• PMID: 6970075 (Publication Type: Journal Article, Research Support, U.S. Gov't, P.H.S.)

Chemical References

• Leucovorin
• Methotrexate

Topics

• Aged
• Carcinoma (drug therapy)
• Drug Evaluation
• Drug Therapy, Combination
• Female
• Humans
• Leucovorin (therapeutic use)
• Lung Neoplasms (drug therapy)
• Male
• Methotrexate (blood, therapeutic use)
• Middle Aged